Concert Pharmaceuticals (NASDAQ:CNCE) Now Covered by StockNews.com
Research analysts at StockNews.com began coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock. CNCE has been the topic of a number of other reports. Truist Financial cut Concert Pharmaceuticals from a “buy” rating […]